Extracorporeal Photopheresis as a Possible Therapeutic Approach for Adults with Severe and Critical COVID-19 Non-Responsive to Standard Treatment: A Pilot Investigational Study
<b<Background:</b< The optimal approach for adult patients hospitalized with severe and critical coronavirus disease 2019 (COVID-19), non-responsive to antiviral and immunomodulatory drugs, is not well established. Our aim was to evaluate feasibility and safety of extracorporeal photopheresis (ECP) in this setting. <b<Methods:</b< A prospective, single-center investigational study was performed between 2021 and 2022 at a tertiary referral center for COVID-19. Patients diagnosed with COVID-19 were screened, and cases with severe or critical disease fulfilling pre-defined clinical and biochemical criteria of non-response for <5 days, despite remdesivir, dexamethasone and immunomodulation (tocilizumab, baricitinib, ruxolitinib), were consecutively enrolled. After patient inclusion, two ECP sessions on two consecutive days per week for 2 weeks were applied. Patients were followed-up per protocol from study inclusion, and clinical, virological and radiological outcomes were assessed at the end of treatment (EOT) +28 days. <b<Results:</b< A total of seven patients were enrolled. At inclusion, four out of seven (57.1%) were admitted to the ICU, all patients had ongoing cytokine storm. Additionally, 3/7 (42.9%) had radiological progression on chest CT. At EOT+28 days, 2/7 (28.6%) patients died due to non-ECP-related causes. Among the survivors, no additional requirement for intensive care unit admission or radiological progression was observed, and invasive mechanical ventilation could be weaned off in 1/5 (20.0%). All patients achieved whole-blood SARS-CoV-2 RNAemia clearance, while 3/7 (42.9%) no longer showed detectable respiratory SARS-CoV-2 RNA. According to immune biomarker profiling, ECP mainly facilitated a decrease in plasma IL-6 and IL-17A levels, as well as the physiological regeneration of peripheral blood immunocyte subpopulations, notably CD8+/CD45RO+ memory T-cells. No safety signals were identified. <b<Conclusions:</b< ECP appears to be a safe and feasible option for adults hospitalized with severe or critical COVID-19 who do not respond to pharmacological interventions. Further trial data are warranted to assess its optimal use. <b<Trial registration:</b< ClinicalTrials.gov NCT05882331 (retrospectively registered)..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Journal of Clinical Medicine - 12(2023), 15, p 5000 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bálint Gergely Szabó [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
|
|---|
| doi: |
10.3390/jcm12155000 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ093697937 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ093697937 | ||
| 003 | DE-627 | ||
| 005 | 20240413015133.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240413s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcm12155000 |2 doi | |
| 035 | |a (DE-627)DOAJ093697937 | ||
| 035 | |a (DE-599)DOAJ0daed66ef9ab402eb199e59fb1612684 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a Bálint Gergely Szabó |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Extracorporeal Photopheresis as a Possible Therapeutic Approach for Adults with Severe and Critical COVID-19 Non-Responsive to Standard Treatment: A Pilot Investigational Study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a <b<Background:</b< The optimal approach for adult patients hospitalized with severe and critical coronavirus disease 2019 (COVID-19), non-responsive to antiviral and immunomodulatory drugs, is not well established. Our aim was to evaluate feasibility and safety of extracorporeal photopheresis (ECP) in this setting. <b<Methods:</b< A prospective, single-center investigational study was performed between 2021 and 2022 at a tertiary referral center for COVID-19. Patients diagnosed with COVID-19 were screened, and cases with severe or critical disease fulfilling pre-defined clinical and biochemical criteria of non-response for <5 days, despite remdesivir, dexamethasone and immunomodulation (tocilizumab, baricitinib, ruxolitinib), were consecutively enrolled. After patient inclusion, two ECP sessions on two consecutive days per week for 2 weeks were applied. Patients were followed-up per protocol from study inclusion, and clinical, virological and radiological outcomes were assessed at the end of treatment (EOT) +28 days. <b<Results:</b< A total of seven patients were enrolled. At inclusion, four out of seven (57.1%) were admitted to the ICU, all patients had ongoing cytokine storm. Additionally, 3/7 (42.9%) had radiological progression on chest CT. At EOT+28 days, 2/7 (28.6%) patients died due to non-ECP-related causes. Among the survivors, no additional requirement for intensive care unit admission or radiological progression was observed, and invasive mechanical ventilation could be weaned off in 1/5 (20.0%). All patients achieved whole-blood SARS-CoV-2 RNAemia clearance, while 3/7 (42.9%) no longer showed detectable respiratory SARS-CoV-2 RNA. According to immune biomarker profiling, ECP mainly facilitated a decrease in plasma IL-6 and IL-17A levels, as well as the physiological regeneration of peripheral blood immunocyte subpopulations, notably CD8+/CD45RO+ memory T-cells. No safety signals were identified. <b<Conclusions:</b< ECP appears to be a safe and feasible option for adults hospitalized with severe or critical COVID-19 who do not respond to pharmacological interventions. Further trial data are warranted to assess its optimal use. <b<Trial registration:</b< ClinicalTrials.gov NCT05882331 (retrospectively registered). | ||
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a severe acute respiratory syndrome coronavirus 2 | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a coronavirus disease 2019 | |
| 650 | 4 | |a ECP | |
| 650 | 4 | |a <i<extracorporeal photopheresis</i< | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a Péter Reményi |e verfasserin |4 aut | |
| 700 | 0 | |a Szabolcs Tasnády |e verfasserin |4 aut | |
| 700 | 0 | |a Dorina Korózs |e verfasserin |4 aut | |
| 700 | 0 | |a László Gopcsa |e verfasserin |4 aut | |
| 700 | 0 | |a Marienn Réti |e verfasserin |4 aut | |
| 700 | 0 | |a Andrea Várkonyi |e verfasserin |4 aut | |
| 700 | 0 | |a János Sinkó |e verfasserin |4 aut | |
| 700 | 0 | |a Botond Lakatos |e verfasserin |4 aut | |
| 700 | 0 | |a János Szlávik |e verfasserin |4 aut | |
| 700 | 0 | |a Gabriella Bekő |e verfasserin |4 aut | |
| 700 | 0 | |a Ilona Bobek |e verfasserin |4 aut | |
| 700 | 0 | |a István Vályi-Nagy |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Journal of Clinical Medicine |d MDPI AG, 2013 |g 12(2023), 15, p 5000 |w (DE-627)DOAJ000006793 |x 20770383 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:15, p 5000 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/jcm12155000 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/0daed66ef9ab402eb199e59fb1612684 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.mdpi.com/2077-0383/12/15/5000 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2077-0383 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 15, p 5000 | ||